Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have received a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $78.00.

LNTH has been the subject of a number of research reports. Truist Financial increased their price target on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Mizuho raised their target price on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Finally, The Goldman Sachs Group set a $77.00 price target on shares of Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $67.51 on Friday. The firm has a market cap of $4.48 billion, a price-to-earnings ratio of 28.37 and a beta of -0.11. The firm has a fifty day moving average price of $63.52 and a 200 day moving average price of $60.57. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $111.29. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 EPS for the quarter, hitting the consensus estimate of $1.27. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The business had revenue of $384.01 million for the quarter, compared to analysts’ expectations of $363.42 million. During the same quarter in the previous year, the company earned $1.70 EPS. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. As a group, sell-side analysts expect that Lantheus will post 6.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Elevation Point Wealth Partners LLC bought a new stake in shares of Lantheus in the second quarter worth $26,000. Osterweis Capital Management Inc. acquired a new position in Lantheus during the 2nd quarter worth $36,000. Hantz Financial Services Inc. grew its holdings in Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 396 shares in the last quarter. First Horizon Corp bought a new stake in shares of Lantheus in the 3rd quarter worth about $26,000. Finally, Farther Finance Advisors LLC raised its stake in shares of Lantheus by 71.4% in the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 275 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.